insights_auto
Bakit bumaba ang GIFLF 5.24%?
Tingnan ang Higit pang Detalyechevron_right
GIFLF:OTCMKTS
Grifols SA Class A
$10.55
arrow_downward
-5.24%(-0.58) 1D
Okt 13, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa GIFLF...
Buksan
$10.55
Mataas
$10.55
Mababa
$10.55
Mkt. cap
6.63B
Avg. na dami
543.00
Dami
9.70K
Mataas nang 52-wk
$12.90
Mababa nang 52-wk
$10.13
Beta
0.90
Mga natitirang share
426.13M
Bilang ng mga empleyado
25K
Buksan
$10.55
Mataas
$10.55
Mababa
$10.55
Mkt. cap
6.63B
Avg. na dami
543.00
Dami
9.70K
Mataas nang 52-wk
$12.90
Mababa nang 52-wk
$10.13
Beta
0.90
Mga natitirang share
426.13M
Bilang ng mga empleyado
25K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketBeat
·
11 oras ang nakalipas
Grifols, S.A. (NASDAQ:GRFS) Shares Shorted: Short Interest Up 105.0% in September
ad-hoc-news.de
·
1 araw ang nakalipas
Wall Street Zen downgrades Grifols stock from Buy to Hold
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Tungkol sa Grifols SA Class A